Esthesioneuroblastoma, Olfactory: all 29 studies
Page 1 of 1. Open to participants first (10), then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory NeuroblastomaNot yet recruitingNCT07527169Phase 2
- An International Study on Pediatric Patients With Rare Tumors.RecruitingNCT07072143
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingNCT06814496Phase 1/2
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
- [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck CancersRecruitingNCT06479811Phase 1
- Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)RecruitingNCT06255210Phase 2
- Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsRecruitingNCT06176989Phase 2
- A Natural History Study of Children and Adults With Olfactory NeuroblastomaRecruitingNCT04755205
- 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.RecruitingNCT04081701Phase 4
- Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy ParticipantsRecruitingNCT00898638
- Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).CompletedNCT05012098Phase 2Results posted
- 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyCompletedNCT01806675Phase 1/2Results posted
- Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
- A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory NeuroblastomaWithdrawnNCT06308575Phase 2
- Long-Term Longitudinal QoL in Patients Undergoing EEAActive, not recruitingNCT04087902
- Esthesioneuroblastoma: Outcomes After TreatmentWithdrawnNCT02580136
- Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck CancerCompletedNCT01637194Phase 1
- Intensity-Modulated or Proton Radiation Therapy for Sinonasal MalignancyActive, not recruitingNCT01586767Not applicable
- Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerTerminatedNCT00499733Early Phase 1
- Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck CancerCompletedNCT00470496Phase 1
- Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
- Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
- Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
- Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
- Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
- Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
- Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerCompletedNCT00021333Phase 2
- Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2/3